Coastlands Capital LP has disclosed a 5.69% ownership stake in Kalaris Therapeutics, Inc. This significant investment, amounting to 1,355,119 shares, was reported in a recent Schedule 13G filing. The move underscores the increasing interest in the biological products sector, particularly as Kalaris continues to develop its portfolio in life sciences.
Kalaris Therapeutics, based in Berkeley Heights, NJ, specializes in biological products, specifically those that do not involve diagnostic substances. The company has undergone several name changes in the past, previously known as Allovir, Inc. and ViraCyte, Inc. This latest filing, dated October 26, 2026, is part of a series of disclosures by Coastlands Capital, which has been actively managing its investments in Kalaris throughout October.
The Schedule 13G filing indicates that Coastlands Capital Partners LP, along with its affiliates, beneficially owns 5.69% of Kalaris’s common stock. The total number of shares outstanding for Kalaris as of August 4, 2026, was reported to be 23,804,981, as disclosed in Kalaris’s quarterly report filed on August 11, 2026. Coastlands Capital’s investment strategy appears to focus on long-term growth within the life sciences sector, which is experiencing a surge in investor interest.
According to the filing, Coastlands Capital LP is the investment adviser for its affiliated entities and is led by Matthew D. Perry, who is also identified as a control person in the filing. The investment firm has expressed its intent to file jointly with the SEC for any future transactions involving Kalaris’s securities, indicating a proactive approach to managing its stake.
This investment by Coastlands Capital may influence other investors in the biological products industry, as it highlights the potential for growth and innovation in this sector. As more firms recognize the value of investing in companies like Kalaris, competition for shares may increase, potentially leading to a more dynamic market environment.
The filing does not specify what actions Coastlands Capital may take next regarding its investment in Kalaris Therapeutics. However, the continued monitoring of Kalaris’s performance and market conditions will likely be crucial for Coastlands as it navigates its investment strategy.